Pharmacogenomic profiling of intra-tumor heterogeneity using a large organoid biobank of liver cancer
Yang et al. reveal the genomic and phenotypic inter- and intra-tumor heterogeneity of liver cancer using a biobank of 399 tumor organoids from 144 patients. Pharmacogenomic profiling and mechanistic investigation generate biomarker panels predicting drug responses and identify c-Jun overexpression as a key factor leading to lenvatinib resistance.